Efficacy of long-term prednisone therapy in patients with chronic inflammatory demyelinating polyneuropathy (CIDP): a retrospective cohort study

被引:1
|
作者
Lopez-Hernandez, Juan C. [1 ,2 ]
Mercado-Pompa, Andres [2 ]
Perez-Torres, Teresa [1 ,2 ]
Galnares-Olalde, Javier A. [1 ,2 ]
Vargas-Canas, Edwin S. [1 ,2 ]
机构
[1] Inst Nacl Neurol & Neurocirug, Dept Enfermedades Neuromusculares, Ciudad De Mexico, Mexico
[2] Inst Nacl Neurol & Neurocirug, Dept Neurol, Ciudad De Mexico, Mexico
关键词
Chronic; CIDP; Neuropathy; Prednisone; Prognosis; Treatment; DIAGNOSIS; NEUROPATHIES; REMISSION; PROGNOSIS;
D O I
10.33588/rn.7308.2021261
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Patients with CIDP respond adequately to steroid therapy and intravenous immunoglobulin (IVIG). However, few patients have access to IVIG in developing countries. little information exists about the clinical response to steroid therapy in Latin American countries. Objective. to describe the long-term functional clinical response (24 months) to prednisone therapy in CIDP patients. Material and methods. A retrospective cohort was conducted. Selection included patients with definitive CIDP diagnosis according to European criteria from the Neuromuscular Diseases clinic of the National Institute of Neurology and Neurosurgery between January 2016 and December 2020. Good response to steroid therapy was defined as with improvement in at least one point on the GBS disability score. Poor response to steroid therapy was defined as patients who did not show improvement in at least one point on the GBS disability score. Patients were evaluated at 3, 6, 12, 18 and 24 months. Results. Forty-seven patients with CIDP were included. Half of them were male and mean age was 46 +/- 15 years. Mean time since symptom onset to diagnosis was 6 (IQR 2-12) months. The most common clinical variant was sensory-motor 57.4%, followed by acute-onset CIDP 21.3% and atypical variants 21.2%. At diagnosis our patients presented: mean GBS disability score of 3 (2.25-4) points, MRC score 39.5 +/- 12 points, independent gait in 17%, mean prednisone dose of 50 mg (32.5-50). Twenty-four months after prednisone therapy, a less mean GBS disability score -1(0-2) points-, mean MRC score 56.3 +/- 5.1 points, independent gait 93% and prednisone dose 1 (0-5) mg. Patients with poor three-month functional clinical response had a delay in diagnosis > 6 months (64.7% vs 27.5%) and atypical clinical variants (47% vs 6.8%). Conclusion. CIDP patients treated with prednisone have good long-term functional clinical response. Delay in diagnosis and atypical variant are common clinical characteristics for poor functional clinical response in treatment with prednisone.
引用
收藏
页码:275 / 281
页数:7
相关论文
共 50 条
  • [1] LONG-TERM IV IMMUNOGLOBULIN TREATMENT IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY (CIDP)
    van Doorn, P. A.
    Kuitwaard, K.
    Dippel, D. W. J.
    Vermeulen, M.
    [J]. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, 2014, 19 (03) : 284 - 285
  • [2] Short and long-term response to intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy (CIDP):: a retrospective analysis of 101 patients
    Fagniez, O
    Nahum, L
    Lozeron, P
    Denier, C
    Lacroix, C
    Adams, D
    Planté-Bordeneuve, V
    Said, G
    [J]. JOURNAL OF NEUROLOGY, 2005, 252 : 156 - 156
  • [3] Efficacy of azathioprine and methotrexate in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)
    Mehreen, Shamza
    Iftikhar, Sadaf
    Muhammad, Ali
    Siddique, Rana Aatif
    Shahid, Saman
    [J]. PAKISTAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2023, 36 (04) : 1361 - 1365
  • [4] A retrospective analysis of the long-term course of chronic inflammatory demyelinating polyneuropathy
    Melnik, E.
    Arestova, A.
    Grishina, D.
    Suponeva, N.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 826 - 826
  • [5] LONG-TERM OUTCOME IN CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY PATIENTS TREATED WITH INTRAVENOUS IMMUNOGLOBULIN: A RETROSPECTIVE STUDY
    Querol, Luis
    Rojas-Garcia, Ricard
    Casasnovas, Carlos
    Jose Sedano, Maria
    Luis Munoz-Blanco, Jose
    Antonia Alberti, Maria
    Paradas, Carmen
    Sevilla, Teresa
    Pardo, Julio
    Luis Capablo, Jose
    Sivera, Rafael
    Guerrero, Antonio
    Gutierrez-Rivas, Eduardo
    Illa, Isabel
    [J]. MUSCLE & NERVE, 2013, 48 (06) : 870 - 876
  • [6] Long-term treatment in chronic inflammatory demyelinating polyneuropathy
    Baumann, A.
    Hess, C. W.
    Andresen, I.
    Sturzenegger, M.
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2008, 15 : 161 - 161
  • [7] Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy
    Pavesi, G
    Cattaneo, L
    Marbini, A
    Gemignani, F
    Mancia, D
    [J]. JOURNAL OF NEUROLOGY, 2002, 249 (06) : 777 - 779
  • [8] Long-term efficacy of Interferon-alpha in chronic inflammatory demyelinating polyneuropathy
    Giovanni Pavesi
    Luigi Cattaneo
    Adriana Marbini
    Franco Gemignani
    Domenico Mancia
    [J]. Journal of Neurology, 2002, 249 : 777 - 779
  • [9] Clinical characteristics in a cohort of patients with chronic inflammatory demyelinating polyneuropathy: a retrospective study
    Alvarado-Garcia, Marco A.
    Marquez-Vargas, Mitzi G.
    Millan-Padilla, Jesus
    Olivares-de la Torre, Hector
    Hernandez-Juarez, Leticia M.
    Bazan-Rodriguez, Lisette
    [J]. REVISTA MEXICANA DE NEUROCIENCIA, 2024, 25 (02): : 29 - 34
  • [10] A Retrospective Study of Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP): Identifying Ultrasonographic Features for Diagnosis and Prognosis
    Crump, Nicholas
    Cartwright, Michael
    [J]. NEUROLOGY, 2018, 90